Ulipristal
Ella, Esmya (ulipristal) is a small molecule pharmaceutical. Ulipristal was first approved as Ella on 2010-08-13. It has been approved in Europe to treat leiomyoma. The pharmaceutical is active against progesterone receptor. Ella's patents are valid until 2030-06-12 (FDA).
| Trade Name | Esmya |
|---|---|
| Common Name | Ulipristal |
| Indication | leiomyoma |
| Drug Class | Steriodal compounds acting on progesterone receptors (excluding -gest- compounds) |
